 JUPITER, Fla., June 28, 2021 GLOBE NEWSWIRE -- Dyadic International, Inc. Dyadic, we, us, our, or the Company NASDAQ: DYAI, a global biotechnology company focused on deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs, announced today findings from the Zoonotic Anticipation and Preparedness Initiative ZAPI project which has been published in VACCINES, a leading peer-reviewed scientific journal. 